• Entrada Therapeutics held its annual shareholder meeting on June 10, 2026.
• Shareholders adopted amendments to the 2021 Stock Option and Incentive Plan, adjusting the evergreen share increase formula to include outstanding pre-funded warrants.
• Shareholders adopted amendments to the 2021 Employee Stock Purchase Plan, making the same evergreen formula change to include outstanding pre-funded warrants.
• Shareholders ratified Ernst & Young as independent registered public accounting firm for the year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-072326), on June 10, 2026, and is solely responsible for the information contained therein.